Kairos Pharma Ltd.
KAPA | AMEX
$1.71
-$0.08 (-4.47%)
Sep 22, 2026, 11:33 AM ET · Market open
TTM Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 30, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 | Q2 2023 Jun 29, 2023 | Q1 2023 Mar 30, 2023 | Q4 2022 Dec 30, 2022 | Q3 2022 Sep 29, 2022 | Q2 2022 Jun 29, 2022 | Q1 2022 Mar 30, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | -80K | -80K | -120K | 40K | 80K | 120K | 160K | 160K | 160K | 120K | 80K | 40K | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 80K | 80K | 120K | -40K | -80K | -120K | -160K | -160K | -160K | -120K | -80K | -40K | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -6.03M | -6.07M | -5.72M | -5.6M | -4.55M | -3.32M | -2.34M | -1.98M | -1.89M | -1.88M | -1.71M | -805K | -642K | -550K | -571K | -391K | -267K | -147K |
Interest Income | 152K | 157K | 125K | 75K | 38K | 4K | n/a | n/a | n/a | n/a | n/a | 4K | 4K | 4K | 4K | n/a | n/a | n/a |
Pretax Income | -5.81M | -5.84M | -5.45M | -5.06M | -4.71M | -3.54M | -2.6M | -2.74M | -2.01M | -1.99M | -1.81M | -890K | -812K | -961K | -1.05M | -854K | -620K | -235K |
Net Income | -5.81M | -5.84M | -5.45M | -5.06M | -4.71M | -3.54M | -2.6M | -2.74M | -2.01M | -1.99M | -1.81M | -890K | -812K | -961K | -1.05M | -854K | -620K | -235K |
Selling & General & Admin | 3.43M | 3.55M | 3.28M | 3.67M | 3.22M | 2.42M | 1.76M | 1.57M | 1.46M | 1.51M | 1.55M | 642K | 552K | 490K | 484K | 352K | 228K | 114K |
Research & Development | 2.45M | 2.33M | 2.14M | 1.77M | 1.18M | 742K | 414K | 249K | 268K | 241K | 82K | 123K | 90K | 60K | 87K | 39K | 39K | 33K |
Other Expenses | 235K | 275K | 428K | 120K | 80K | 40K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 6.11M | 6.15M | 5.84M | 5.56M | 4.47M | 3.2M | 2.18M | 1.82M | 1.73M | 1.76M | 1.63M | 765K | 642K | 550K | 571K | 391K | 267K | 147K |
Interest Expense | n/a | n/a | n/a | 133K | 797K | 828K | 864K | 760K | 121K | 114K | 98K | 69K | 154K | 395K | 463K | 463K | 353K | 88K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 6.03M | 6.07M | 5.72M | 5.6M | 4.55M | 3.32M | 2.34M | 1.98M | 1.89M | 1.88M | 1.71M | 805K | 642K | 550K | 571K | 391K | 267K | 147K |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 3.06M | 3M | 2.63M | 2.89M | 2.46M | 2.27M | 1.96M | 1.56M | 1.83M | 1.51M | 1.5M | 1.6M | 1.48M | 1.48M | 1.48M | 1.46M | 1.45M | 1.45M |
Shares Outstanding (Diluted) | 3.06M | 3M | 2.63M | 2.89M | 2.46M | 2.27M | 1.96M | 1.56M | 1.83M | 1.51M | 1.5M | 1.6M | 1.48M | 1.48M | 1.48M | 1.46M | 1.45M | 1.45M |
EPS (Basic) | -1.94 | -2.09 | -2.10 | -2.12 | -2.31 | -1.87 | -1.52 | -1.79 | -1.32 | -1.34 | -1.22 | -0.59 | -0.55 | -0.66 | -0.72 | -0.59 | -0.43 | -0.16 |
EPS (Diluted) | -1.94 | -2.09 | -2.10 | -2.12 | -2.31 | -1.87 | -1.52 | -1.79 | -1.32 | -1.34 | -1.22 | -0.59 | -0.55 | -0.66 | -0.72 | -0.59 | -0.43 | -0.16 |
EBITDA | -5.66M | -5.68M | -5.29M | -4.77M | -3.75M | -2.55M | -1.58M | -1.82M | -1.73M | -1.72M | -1.55M | -661K | -498K | -406K | -427K | -271K | -187K | -107K |
EBIT | -5.81M | -5.84M | -5.45M | -4.93M | -3.91M | -2.71M | -1.74M | -1.98M | -1.89M | -1.88M | -1.71M | -821K | -658K | -566K | -587K | -391K | -267K | -147K |
Depreciation & Amortization | 142K | 160K | 160K | 160K | 160K | 160K | 160K | 160K | 160K | 160K | 160K | 160K | 160K | 160K | 160K | 120K | 80K | 40K |
Add to Watchlist
Select watchlists to add or remove KAPA